CYBN
Bullish signalScored 2026-10-20 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Cybin Inc.
- Nom
- Cybin Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- AMEX
- Capitalisation
- $413.0M
- Employés
- 50
- PDG
- Eric So
- Site web
- https://www.cybin.com
- Marché
- ALECIMDXIPHAMISTMOLNNKTX
Cybin Inc. is a biopharmaceutical firm dedicated to pioneering treatments that leverage psychedelic compounds. Its research and development portfolio encompasses several key candidates: CYB003, a modified psilocybin compound targeting major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine designed to alleviate anxiety conditions; and CYB005, a phenethylamine derivative aimed at combating neuroinflammation. Beyond its drug pipeline, Cybin has also conceived EMBARK, an innovative form of psychotherapy enhanced by psychedelics. The enterprise's primary base of operations is situated in Toronto, Canada.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 90000 titres (~1042677 USD)
- Insiders
- Glavine Paul
- Total bought
-
$1,042,677
Avg buy (VWAP, 90d window) $12.24 vs last close $7.73 (-36.8%)
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-31
- Liquidity
- Thin $7,183,625/day · 20d vol
- Last synced
-
2026-10-21 21:10:20
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-21 | Halstead Michael | Buy · P | 100,000 | $13.47 | $1,347,050 | Form 4 |
| 2026-09-08 | Glavine Paul | Buy · P | 100,000 | $12.47 | $1,247,190 | Form 4 |
| 2026-09-08 | So Eric H. L. | Buy · P | 100,000 | $12.39 | $1,238,670 | Form 4 |
| 2026-09-04 | So Eric H. L. | Buy · P | 100,000 | $12.09 | $1,208,900 | Form 4 |
| 2026-09-03 | Glavine Paul | Buy · P | 100,000 | $11.78 | $1,178,280 | Form 4 |
| 2026-09-01 | So Eric H. L. | Buy · P | 95,000 | $11.80 | $1,121,475 | Form 4 |
| 2026-08-31 | Glavine Paul | Buy · P | 90,000 | $11.59 | $1,042,677 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bullish signalScored 2026-10-20 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
CYBN presents a compelling near-term event-driven setup driven by an imminent Phase 3 data readout for HLP003 in depression and a significant insider purchase (~$1.04M), suggesting informed confidence in the upcoming…
The first sentence of the analysis written for CYBN on 2026-10-20 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Supports a bullish reading. Current ratio 7.75 · operating margin 0.0%
Suggested stop 6.99, nearest stored support minus 0.5 ATR(9.5% under the last close). Reward/risk to the next stored resistance is 0.37. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-09-22 Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board Cybin NASDAQ: HELP, doing business as Helus Pharma, held its Annual General and Special Meeting of Shareholders, where shareholders were asked to consider resolutions related to the company''s auditor, board size, corporate name and director elections.
- 2026-09-21 Cybin Eyes Q4 Phase 3 Data for Depression Drug HLP003 Cybin NASDAQ: HELP executives outlined plans for its late-stage depression program, including an expected fourth-quarter Phase 3 data readout for HLP003, during H.C. Wainwright''s 28th Annual Global Investment Conference.
- 2026-09-20 Cybin Eyes Q4 Phase III Depression Readout as Psychedelic Pipeline Advances Helus Pharma Chief Executive Officer Michael Halstead said the company expects a pivotal Phase III readout for its HLP003 program in adjunctive major depressive disorder in the fourth quarter, describing the data as a key near-term catalyst for the company''s mental health treatment pipeline.
Market snapshot
Financial ratios
| Metric | Trend | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 23.1% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | -3728.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | -3722.3% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | -3592.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | -3729.2% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | -3729.2% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | -3729.2% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | -3729.2% | |
| Current Ratio | 7.749 | 21.646 | 2.932 | 11.909 | 13.568 | |
| Quick Ratio | 7.749 | 21.646 | 2.771 | 11.952 | 13.568 | |
| Solvency Ratio | -5.260 | -7.692 | -5.031 | -11.888 | -5.367 | |
| Cash Ratio | 6.304 | 20.700 | 2.103 | 10.947 | 13.067 | |
| Price To Earnings Ratio | -14.952 | -5.575 | -89.877 | -90.284 | -0.000 | |
| Price To Earnings Growth Ratio | 0.177 | -0.003 | 1.840 | 0.903 | -0.000 | |
| Forward Price To Earnings Growth Ratio | 0.177 | -0.003 | 1.840 | 0.903 | -0.000 | |
| Price To Earnings Diluted Ratio | -14.952 | -2.316 | -89.877 | -90.284 | -0.000 | |
| Price To Earnings Diluted Growth Ratio | 0.160 | -0.001 | 1.840 | 0.903 | -0.000 | |
| Price To Book Ratio | 7.130 | 13.845 | 76.015 | 85.279 | 0.000 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.001 | |
| Price To Free Cash Flow Ratio | -16.378 | -58.057 | -80.182 | -337.233 | -0.000 | |
| Price To Operating Cash Flow Ratio | -16.696 | -58.656 | -81.105 | -341.327 | -0.000 | |
| Debt To Assets Ratio | 0.000 | 0.001 | 0.000 | 0.000 | 0.000 | |
| Debt To Equity Ratio | 0.000 | 0.001 | 0.000 | 0.000 | 0.000 | |
| Debt To Capital Ratio | 0.000 | 0.001 | 0.000 | 0.000 | 0.000 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.090 | 1.035 | 1.117 | 1.104 | 1.070 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.027 | |
| Operating Cash Flow Ratio | -4.730 | -6.825 | -5.717 | -3.883 | -3.883 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | -22.022 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.019 | 1.010 | 1.012 | 1.012 | 1.012 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | -3,216.100 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | -3,103.500 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.000 | -236.797 | 0.000 | 0.000 | 0.000 | |
| Capital Expenditure Coverage Ratio | -51.526 | -97.054 | -86.937 | -82.368 | -82.368 | |
| Dividend Paid And Capex Coverage Ratio | -51.526 | -97.054 | -86.937 | -82.368 | -82.368 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -10.908 | -48.885 | -71.193 | -101.159 | 1.991 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | ▼-4.6% |
| Ebit Margin | 0.0% | 0.0% | ▲745.6% |
| Ebitda Margin | 0.0% | 0.0% | ▲744.5% |
| Operating Profit Margin | 0.0% | 0.0% | ▲718.4% |
| Pretax Profit Margin | 0.0% | 0.0% | ▲745.8% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | ▲745.8% |
| Net Profit Margin | 0.0% | 0.0% | ▲745.8% |
| Bottom Line Profit Margin | 0.0% | 0.0% | ▲745.8% |
| Current Ratio | 7.749 | ▼-13.897 | ▼-3.812 |
| Quick Ratio | 7.749 | ▼-13.897 | ▼-3.788 |
| Solvency Ratio | -5.260 | ▲2.432 | ▲1.788 |
| Cash Ratio | 6.304 | ▼-14.396 | ▼-4.320 |
| Price To Earnings Ratio | -14.952 | ▼-9.377 | ▲25.186 |
| Price To Earnings Growth Ratio | 0.177 | ▲0.180 | ▼-0.406 |
| Forward Price To Earnings Growth Ratio | 0.177 | ▲0.180 | ▼-0.406 |
| Price To Earnings Diluted Ratio | -14.952 | ▼-12.636 | ▲24.534 |
| Price To Earnings Diluted Growth Ratio | 0.160 | ▲0.160 | ▼-0.421 |
| Price To Book Ratio | 7.130 | ▼-6.715 | ▼-29.324 |
| Price To Sales Ratio | 0.000 | 0.000 | ▼-0.000 |
| Price To Free Cash Flow Ratio | -16.378 | ▲41.680 | ▲81.993 |
| Price To Operating Cash Flow Ratio | -16.695 | ▲41.960 | ▲82.861 |
| Debt To Assets Ratio | 0.000 | ▼-0.001 | ▼-0.000 |
| Debt To Equity Ratio | 0.000 | ▼-0.001 | ▼-0.000 |
| Debt To Capital Ratio | 0.000 | ▼-0.001 | ▼-0.000 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.090 | ▲0.056 | ▲0.007 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | ▼-0.005 |
| Operating Cash Flow Ratio | -4.730 | ▲2.096 | ▲0.278 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | ▲4.404 |
| Free Cash Flow Operating Cash Flow Ratio | 1.019 | ▲0.009 | ▲0.006 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | ▲643.220 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲620.700 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 0.000 | ▲236.797 | ▲47.359 |
| Capital Expenditure Coverage Ratio | -51.526 | ▲45.528 | ▲28.524 |
| Dividend Paid And Capex Coverage Ratio | -51.526 | ▲45.528 | ▲28.524 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -10.908 | ▲37.977 | ▲35.123 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.69B | $4.04B | $3.67B | $6.49B | $498 | |
| Enterprise value | $1.56B | $3.83B | $3.65B | $6.44B | -$64.0M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | -74.10x | |
| EV / Op. cash flow | -15.36x | -55.63x | -80.74x | -338.51x | 3.37x | |
| EV / Free cash flow | -15.07x | -55.06x | -79.82x | -334.45x | 3.33x | |
| EV / EBITDA | -10.91x | -48.88x | -71.19x | -101.16x | 1.99x | |
| Net debt / EBITDA | 0.95x | 2.66x | 0.32x | 0.84x | 1.99x | |
| Current ratio | 7.75x | 21.65x | 2.93x | 11.91x | 13.57x | |
| Income quality | 0.90x | 0.88x | 0.95x | 0.28x | 0.59x | |
| Graham net-net | $1 | $1 | $0 | $0 | $5.9M | |
| Tax burden | 100.0% | 100.0% | 84.3% | 105.6% | 100.0% | |
| Interest burden | 79.0% | 99.0% | 92.2% | 105.9% | 100.0% | |
| Working capital | $144.6M | $208.4M | $15.3M | $53.5M | $61.6M | |
| Invested capital | $237.2M | $291.9M | $40.7M | $79.1M | $87.2M | |
| Return on assets | -43.7% | -25.9% | -74.3% | -85.0% | -35.0% | |
| Operating ROA | -51.1% | -44.3% | -74.7% | -72.5% | -66.2% | |
| Return on tangible assets | -68.1% | -35.6% | -138.4% | -121.1% | -48.1% | |
| Return on equity | -47.7% | -26.7% | -83.0% | -93.8% | -37.4% | |
| Return on invested capital | -60.3% | -27.0% | -112.0% | -80.7% | -35.6% | |
| Return on capital employed | -60.3% | -27.0% | -112.0% | -80.6% | -35.6% | |
| Earnings yield | -6.7% | -1.9% | -1.1% | -1.1% | -6470635.4% | |
| Free cash flow yield | -6.1% | -1.7% | -1.2% | -0.3% | -3867520.1% | |
| Capex / Op. cash flow | -1.9% | -1.0% | -1.2% | -1.2% | -1.2% | |
| Capex / Depreciation | 413.9% | 167.5% | 207.2% | 137.5% | 471.4% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 26.7% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 3174.1% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 381.9% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 1337.3% | |
| Intangibles / Total assets | 35.8% | 27.5% | 46.3% | 29.8% | 27.2% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 561d | |
| Days payables outstanding | 23686d | 8441d | 8235d | 11432d | 1535d | |
| Operating cycle | 0d | 0d | 1848d | -461d | 561d | |
| Cash conversion cycle | -23686d | -8441d | -6387d | -11893d | -974d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years